Serina Therapeutics, Inc. 8-K

What Happened
Serina Therapeutics, Inc. announced on January 28, 2026 (8-K filed) that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for SER-252, an investigational therapy for advanced Parkinson’s disease. The IND clearance allows Serina to proceed with regulatory and site-level activities needed to initiate a planned Phase 1b registrational clinical study in patients with advanced Parkinson’s disease. The company filed a related press release as Exhibit 99.1 to the Current Report.

Key Details

• FDA cleared the IND for SER-252 (filing disclosed in 8-K dated January 28, 2026).
• The clearance enables preparation and initiation of a planned Phase 1b registrational clinical study in advanced Parkinson’s disease.
• Press release announcing the clearance is filed as Exhibit 99.1; the 8-K was signed by CEO Steve Ledger.

Why It Matters
IND clearance is a regulatory milestone that permits Serina to move from preclinical and regulatory preparation into human clinical testing for SER-252. For investors, this represents a de-risking step and a potential near-term clinical development catalyst as the company begins site activation and trial initiation for a registrational Phase 1b study. The filing does not include trial timelines, enrollment targets, results, or financial details, so investors should watch for subsequent updates on trial start dates, design, endpoints, and financing.